@article{Sorà_Chiusolo_autore_Giammarco_laurenti_metafuni_innocenti_galli_bacigalupo_sica_2021, title={IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?}, volume={13}, url={https://www.mjhid.org/mjhid/article/view/4702}, DOI={10.4084/MJHID.2021.062}, abstractNote={<p><strong>Abstract </strong></p> <p><strong> </strong></p> <p>Classification of myeloproliferative neoplasms is based on hematologic, histopathologic and molecular characteristics including the presence of the BCR-ABL1 and JAK2 V617F or MPL and CALR. Although the different gene mutations ought to be mutually exclusive, a number of cases with co-occurring BCR-ABL1 and JAK2 V617F or CALR, have been identified with a frequence of 0.2-2.5%in European population .The tyrosine kinase abnormalities appeared to affect independent subclones because imatinib mesylate (IM) treatment induced Ph+-CML remission whereas the JAK2V617F clone either persisted or clinically expanded  after major response of Ph+-clone.</p> <p>Allogeneic stem cell transplantation is at the present the only potentially curative therapy for these patients after therapy with ruxolitinib and TKI inhibitor. We describe the case of 3 young people treated in our institution for coexistence of BCR/ABL chronic myeloid leukemia and another Philadelphia chromosome negative (Ph−) CMPD. They received ruxolitinib, imatinib/nilotinib and allogeneic transplantation with a safe and efficient results.</p>}, number={1}, journal={Mediterranean Journal of Hematology and Infectious Diseases}, author={Sorà, Federica and Chiusolo, Patrizia and autore, Francesco and Giammarco, Sabrina and laurenti, luca and metafuni, elisabetta and innocenti, idanna and galli, eugenio and bacigalupo, andrea and sica, simona}, year={2021}, month={Oct.}, pages={e2021062} }